<DOC>
	<DOCNO>NCT00386230</DOCNO>
	<brief_summary>The purpose study test equivalence short zidovudine ( ZDV ) regimen compare longer , ACTG-076-like , ZDV regimen reduce risk mother-to-child transmission HIV : ass compare safety tolerance long shorten ZDV regimen .</brief_summary>
	<brief_title>Shortened Zidovudine Regimens Prevent Mother-to-Child Transmission HIV Type 1</brief_title>
	<detailed_description>Multicenter , randomize , four arm , double-blind , control study . Consenting pregnant woman test HIV begin pregnancy 26 gestational age ( GA ) . If HIV-positive eligible , woman complete Pre-entry baseline check-up . Enrollment take place 28 week ' gestational age . Women meet selection criterion randomly assign one four study arm ( see ) . AMENDMENT ( March 20 , 1999 ) Data Safety Monitory Board interim review ( March 17 , 1999 ) The DSMB report transmission rate long arm ( long treatment mother baby ) , significantly low short arm ( short treatment mother baby ) discrepancy large previously agree difference , find , would call change study design . In addition , transmission rate remain two arm study similar long arm . The difference find could explain baseline characteristic participant , maternal age , gestational age delivery , birth weight , cesarean section rate , others . The DSMB recommend enrollment shortest arm study terminate , study continued modification design new enrollee would enter one three remain arm . All woman enrol amendment effective deliver March 20th , 1999 , previously randomize Smother-Sinfant arm , unblinded order give infant open label zidovudine 6 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Preinclusion Women eligible PreEntry : evidence HIV infection ( confirmed second sample ) ; present prenatal care 26 week GA , base last menstrual period and/or sonogram result ; intend stay province least 18 month delivery ; provide informed consent ; give write informed consent participate study ; intend carry pregnancy term . preentry criterion ; date enrollment : 28 week GA , base last menstrual period and/or sonogram result ; follow laboratory value within 21 day prior randomization : hemoglobin &gt; 8.0 g/dL ; absolute neutrophil count &gt; 750 cells/mm3 ; SGPT &lt; 5 x upper limit normal ; serum creatinine &lt; 1.5 mg/dL ( woman serum creatinine &gt; 1.5 mg/dL must measure eighthour urine creatinine clearance &gt; 70 mL/min . ) ; agreement breastfeed . AIDS accord Thai Communicable Diseases Control ( CDC ) classification ; preexist maternal/fetal condition contraindicates use ZDV oligohydramnios , unexplained polyhydramnios , fetal hydrops ascites evidence preexist inutero anemia ; clinically significant history intolerance ZDV treatment result discontinuation therapy 4 week ; receipt ZDV current pregnancy indication , woman need ZDV health ( woman follow separately ) ; receipt antiretroviral agent , passive immunotherapy , antiHIV vaccine , cytolytic agent ( usually refer chemotherapy ) , radiation therapy , corticosteroid pregnancy except steroid le 7 ( see Zidovudine Investigator 's Brochure ) ; simultaneous participation another clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>transmission</keyword>
	<keyword>infant</keyword>
	<keyword>HIV</keyword>
	<keyword>pregnancy</keyword>
	<keyword>HIV-1 infection</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>